Morag M. Griffin

St James's Hospital
Leeds, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications

Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag.

Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag.

Journal: NEJM evidence
Published: April 28, 2026

Switching between complement inhibitors in paroxysmal nocturnal hemoglobinuria: Analysis of strategy, efficacy, and safety.

Switching between complement inhibitors in paroxysmal nocturnal hemoglobinuria: Analysis of strategy, efficacy, and safety.

Journal: HemaSphere
Published: March 02, 2026

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.

Journal: American journal of hematology
Published: February 05, 2026

Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan.

Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan.

Journal: Advances in therapy
Published: April 18, 2025

Paroxysmal nocturnal haemoglobinuria: Considerations for optimal pregnancy care. A case report.

Paroxysmal nocturnal haemoglobinuria: Considerations for optimal pregnancy care. A case report.

Journal: Obstetric medicine
Published: March 21, 2025

Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.

Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.

Journal: The Lancet. Haematology
Published: January 13, 2025

First cases of danicopan use in adolescent patients with paroxysmal nocturnal haemoglobinuria.

First cases of danicopan use in adolescent patients with paroxysmal nocturnal haemoglobinuria.

Journal: British journal of haematology
Published: December 17, 2024

Oral iptacopan for paroxysmal nocturnal haemoglobinuria-First real-world experience.

Oral iptacopan for paroxysmal nocturnal haemoglobinuria-First real-world experience.

Journal: British journal of haematology
Published: November 12, 2024

Paroxysmal nocturnal haemoglobinuria in pregnancy-a systematic review with meta analysis.

Paroxysmal nocturnal haemoglobinuria in pregnancy-a systematic review with meta analysis.

Journal: Annals of hematology
Published: October 08, 2024

Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH.

Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH.

Journal: Blood
Published: July 24, 2024

Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria.

Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria.

Journal: Annals of hematology
Published: July 16, 2024

Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates.

Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates.

Journal: Blood advances
Published: July 08, 2024
Showing 1-12 of 52

Last Updated: 09/26/2026